Basic information

Title	Activase® (alteplase) for acute ischemic stroke treatment
Description	Acute ischemic stroke indication: activase is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (ct) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see contraindications in the full prescribing information). acute massive pulmonary embolism indication: activase is indicated in the management of acute massive pulmonary embolism (ampe) in adults: (1) for the lysis of acute pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments of the lungs; (2) for the lysis of pulmonary emboli accompanied by unstable hemodynamics, eg, failure to maintain blood pressure without supportive measures. the diagnosis should be confirmed by objective means, such as pulmonary angiography or noninvasive procedures such as lung scanning. important safety information: contraindications: acute ischemic stroke (ais): treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (ct) scan or other diagnostic imaging method sensitive for the presence of hemorrhage [see contraindications in the full prescribing information]. activase therapy in patients with ais is contraindicated in certain situations (eg, suspicion of subarachnoid hemorrhage on pretreatment evaluation), recent (within 3 months) intracranial or intraspinal surgery, history of intracranial hemorrhage, uncontrolled hypertension at time of treatment, active internal bleeding, known bleeding diathesis (eg, current use of oral anticoagulants, administration of heparin within 48 hours of onset of stroke, platelet count <100,000/mm3) [see contraindications in the full prescribing information]. pulmonary embolism (pe): activase therapy in patients with pe is contraindicated in certain situations (eg, active internal bleeding, history of cerebrovascular accident, recent intracranial or intraspinal surgery or trauma, severe uncontrolled hypertension) [see contraindications in the full prescribing information]. warnings: the risks of activase therapy for all approved indications may be increased and should be weighed against the anticipated benefits in certain conditions [see warnings in the full prescribing information]. acute ischemic stroke (ais): patients with severe neurological deficit (eg, nihss >22) at presentation. there is an increased risk of intracranial hemorrhage in these patients. patients with major early infarct signs on a computerized cranial tomography (ct) scan (eg, substantial edema, mass effect, or midline shift). treatment of patients with minor neurological deficit or with rapidly improving symptoms is not recommended [see warnings in the full prescribing information]. pulmonary embolism (pe): treatment of pe with activase has not been shown to constitute adequate clinical treatment of underlying deep vein thrombosis. the possible risk of reembolization due to the lysis of underlying deep venous thrombi should be considered. precautions (ais): orolingual angioedema has been observed in postmarketing experience in patients treated with activase for ais. patients should be monitored during and for several hours after infusion for signs of orolingual angioedema. adverse reactions: the most common complication during activase therapy is bleeding. should serious bleeding in a critical location (intracranial, gastrointestinal, retroperitoneal, pericardial) occur, activase therapy should be discontinued immediately, along with any concomitant therapy with heparin. death and permanent disability are not uncommonly reported in patients who have experienced stroke (including intracranial bleeding) and other serious bleeding episodes. activase® (alteplase) is the only fda-approved drug for the treatment of acute ischemic stroke.
Analytics ID	UA-6467920
Adsense ID	/
Ip address	72.34.128.173

Traffic

Each day, genentechlytics.us generates 0 pageviews from 0 visitors. The website receives an average of 0 visits and 0 pageviews per month. It is given a rating of E, due to its very low performance.

	Per day	Per week	Per month	Per year
Visitors	0	0	0	0
Pageviews	0	0	0	0

SEO potential

Genentechlytics.us has a Google Pagerank of 0 out of 10 and an Alexa Rank of 0. Although being more and more depreciated as a website quality indicator, a higher PageRank still indicates in most cases the popularity of a website. Sites with high Alexa Rank have high amounts of visitors, indicating that they get good search engine rankings.

The domain name was created 21 years ago (year: 2003, month: 02, day: 11) and has a length of 15 characters. Search engines algorithm gives more credibility and authority to websites whose domain name has been registered for a long time and is still in use (but not parked).

It is given a rating of D, due to its low performance.

Pagerank	0/10
Alexa	#0
Age	21 years, 4 months and 22 days
Index	View pages indexed in : [Google] [Yahoo] [Bing]

Earnings

Genentechlytics.us earns $0 USD a day in advertising revenue. Income from CPC banner ads is $0 USD per year. Yearly income from CPM banner ads is $0 USD. If the website was up for sale, it could be sold for $0 USD. It is given a rating of E, due to its very low performance.

	Per day	Per week	Per month	Per year
CPC	0	0	0	0
CPM	0	0	0	0

Server information

Genentechlytics.us resolves to the IP address 72.34.128.173, which is located in San Jose, United States. The amount of bandwidth used by Genentechlytics is 0 B per day. Thus, we estimates that genentechlytics.us uses a total of 0 server(s), with a cost of $0 USD per month.

Hosting Analysis

Amount of Servers	0
Servers Cost /month	0
Website Bandwidth /day	0 B

Server location

Latitude	37.3394
Longitude	-121.895
City	San Jose
Country	United States

Genentechlytics server location : San Jose, United States (37.3394,-121.895)

Domains on same IP (72.34.128.173)

No.	Domain Name	Visitors
1.	genentechlytics.us (Genentechlytics)	0
2.	lyticportfolio.net (Lyticportfolio)	0